Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Str. 51-59, 1 63225 Langen, Germany.
Int J Pharm. 2014 Aug 5;469(2):240-3. doi: 10.1016/j.ijpharm.2014.03.019. Epub 2014 Mar 6.
The EU regulation (EU 1901/2006 Paediatric Regulation) that entered into force in 2007 has changed the field of medicinal drug development for children in the EU. Five years after its implementation a large number changes due to this regulation have been incorporated by Pharmaceutical Industry considering the development of new candidate drug. This report is a review of changes already implemented and the aspects of paediatric drug development, which still needs to be addressed in future working in the fields to provide better medicines for children.
欧盟法规(欧盟 1901/2006 年儿科法规)于 2007 年生效,改变了欧盟儿童药物开发领域的格局。该法规实施五年后,制药行业在开发新候选药物时考虑到大量变化,已经对其进行了整合。本报告回顾了已经实施的变化以及儿科药物开发的各个方面,这些方面仍需要在未来的工作中加以解决,以为儿童提供更好的药物。